In clinical trials, even tumors without EGFR mutation responded well to EGFR-TKIs, which strongly suggested not only the tumor cells themselves but also potentially tumor-specific immune responses might be the targets of EGFR-TKIs. Here, EGFR is linked to neoplasm.